Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ALX.AX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ALX.AX and 80,000+ other tickers.
See exactly how ALX.AX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ALX.AX and 80,000+ other tickers.
Atlas Arteria Limited specializes in the acquisition, development, and management of toll road assets. Among its key holdings is a 13.4% equity stake in Toll Road Investors Partnership II (TRIP II), the concessionaire responsible for the 22-kilometer Dulles Greenway toll road, situated in Virginia, United States. The company was established in 2009 and operates from its corporate headquarters in Melbourne, Australia. It formally rebranded from Macquarie Atlas Roads Limited to its current name, Atlas Arteria Limited, in May 2018.
No recent news available.